Jazz Pharmaceuticals (NASDAQ:JAZZ) Cut to Sell at Goldman Sachs Group

Goldman Sachs Group lowered shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a neutral rating to a sell rating in a research note issued to investors on Monday, Benzinga reports. Goldman Sachs Group currently has $128.00 target price on the specialty pharmaceutical company’s stock.

A number of other brokerages also recently issued reports on JAZZ. Wolfe Research upgraded Jazz Pharmaceuticals from a peer perform rating to an outperform rating in a research report on Tuesday, July 28th. Oppenheimer began coverage on Jazz Pharmaceuticals in a research report on Thursday, July 30th. They set an outperform rating on the stock. Barclays reiterated a buy rating on shares of Jazz Pharmaceuticals in a research report on Thursday, August 6th. BidaskClub upgraded Jazz Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, September 1st. Finally, HC Wainwright upgraded Jazz Pharmaceuticals from a neutral rating to a buy rating and increased their price target for the stock from $145.00 to $166.00 in a research report on Thursday, July 23rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and sixteen have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $161.81.

Jazz Pharmaceuticals stock opened at $144.13 on Monday. The firm has a market cap of $7.99 billion, a price-to-earnings ratio of 62.39, a price-to-earnings-growth ratio of 1.39 and a beta of 1.26. Jazz Pharmaceuticals has a 52 week low of $86.88 and a 52 week high of $154.24. The business’s 50-day moving average price is $126.56 and its 200 day moving average price is $113.84. The company has a quick ratio of 5.39, a current ratio of 5.62 and a debt-to-equity ratio of 0.66.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported $3.71 EPS for the quarter, topping the consensus estimate of $3.11 by $0.60. The firm had revenue of $562.44 million for the quarter, compared to analyst estimates of $503.19 million. Jazz Pharmaceuticals had a return on equity of 20.47% and a net margin of 6.01%. Jazz Pharmaceuticals’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $4.05 earnings per share. Equities analysts expect that Jazz Pharmaceuticals will post 11.08 EPS for the current year.

In related news, CEO Bruce C. Cozadd sold 500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $134.90, for a total transaction of $67,450.00. Following the transaction, the chief executive officer now owns 336,680 shares in the company, valued at $45,418,132. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last quarter, insiders have sold 3,863 shares of company stock worth $503,644. 4.60% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in the stock. Nissay Asset Management Corp Japan ADV lifted its position in Jazz Pharmaceuticals by 2.2% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 5,734 shares of the specialty pharmaceutical company’s stock worth $572,000 after buying an additional 121 shares in the last quarter. Cardan Capital Partners LLC increased its stake in Jazz Pharmaceuticals by 0.7% during the second quarter. Cardan Capital Partners LLC now owns 19,758 shares of the specialty pharmaceutical company’s stock worth $2,180,000 after acquiring an additional 132 shares during the last quarter. Comerica Bank increased its stake in Jazz Pharmaceuticals by 6.2% during the second quarter. Comerica Bank now owns 3,304 shares of the specialty pharmaceutical company’s stock worth $364,000 after acquiring an additional 192 shares during the last quarter. Eqis Capital Management Inc. increased its stake in Jazz Pharmaceuticals by 3.0% during the first quarter. Eqis Capital Management Inc. now owns 9,936 shares of the specialty pharmaceutical company’s stock worth $1,416,000 after acquiring an additional 293 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. increased its stake in Jazz Pharmaceuticals by 2.3% during the first quarter. Oppenheimer Asset Management Inc. now owns 13,601 shares of the specialty pharmaceutical company’s stock worth $1,357,000 after acquiring an additional 303 shares during the last quarter. Hedge funds and other institutional investors own 92.82% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Read More: What is the float in trading stocks?

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.